Liquidia (LQDA) Stock Price & Analysis

LQDA$57.41-0.71 -1.22%
Medical - PharmaceuticalsGrowth StockHigh Quality
Compare
Market cap$5.17BEnterprise value$3.82BRevenue (TTM)$450.91MMarket position—

Score

72
Bullish
Value
41
Quality
87
Growth
88

AI Analysis

Snapshot

Liquidia is a growth-led story right now — Growth 88/100 is the pillar doing the heavy lifting (overall 72/100) in Medical - Pharmaceuticals. Under the hood: P/E 28.3, plus revenue compounding ~340% annually over recent years. Street targets still imply ~26% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

41
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

88
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

87
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Liquidia Corporation (LQDA) last printed $57.41. Equity value is $5.17B. Trailing earnings multiple 36.82. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$13.22M$7.26M$2.71M$8.07M$739,628.00$12.85M$15.94M$17.49M$14M$158.32M

About

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Liquidia (LQDA) Stock Price & Analysis

LQDA price $57.41 -0.71 -1.22%

Ticker
LQDA
Price
$57.41
Change
-0.71 -1.22%
Market cap
$5.17B
P/E
36.82
Forward P/E
42.67
Dividend yield
0.00%
Beta
0.54
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Stocklytics score
72
Value
41
Quality
87
Growth
88

Stocklytics score rationale: value 41, quality 87, growth 88.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener